Search results for "Cannabinoids"

showing 10 items of 169 documents

Different expression of PPARs in WIN-treated cells: the game of roles

2012

Cancer cells PPAR factors cannabinoids cell deathSettore BIO/10 - Biochimica
researchProduct

Extensive phytocannabinoid profiles of seized cannabis and cannabis-based medicines – Identification of potential distinguishing markers

2021

As the frequency of cannabis-based therapy increases, the ability to distinguish intake of cannabis-based medicines from recreational cannabis use becomes desirable. Minor cannabinoids have been suggested to indicate recreational cannabis use in biological matrices but are unreliable when presumably also present in directly plantderived medicines. Thus, for therapeutics such as medical cannabis, Sativex® and Dronabinol, a more thorough investigation of cannabinoid profiles is required to identify possible distinguishing markers. In this study, 16 phytocannabinoids were quantified in samples of seized and medical cannabis, Sativex® and Dronabinol from two different manufacturers, using a val…

Cannabigerolmedicine.medical_treatmentMedical MarijuanaTetrahydrocannabivarinMass SpectrometryCannabicyclolPathology and Forensic MedicineCannabichromenechemistry.chemical_compoundmedicineCannabidiolHumansDronabinolPrincipal Component AnalysisbiologyTraditional medicineCannabinoidsbusiness.industrybiology.organism_classificationDrug CombinationschemistryCannabinolCannabinoidCannabisDronabinolbusinessLawChromatography Liquidmedicine.drugForensic Science International
researchProduct

Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples

2021

Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines were investigated, in order to identify potential distinguishing markers. Serum samples after use of Sativex®, Dronabinol or medical cannabis were collected and analyzed for 18 different cannabinoids, using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Analytes included delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, …

Cannabigerolprincipal component analysisEndocrinology Diabetes and MetabolismTetrahydrocannabivarin01 natural sciencesBiochemistryMicrobiologyArticleCannabicyclol03 medical and health sciencesCannabichromenechemistry.chemical_compoundcannabinoids0302 clinical medicinemedicineserum concentrations030216 legal & forensic medicineDronabinolLC-MS/MSMolecular BiologybiologyTraditional medicinebusiness.industry010401 analytical chemistrymedical cannabisbiology.organism_classificationSativexQR1-5020104 chemical scienceschemistryCannabinolCannabisDronabinolbusinessCannabidiolmedicine.drugMetabolites
researchProduct

Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

2012

Allosteric modulation of G-protein–coupled receptors represents a key goal of current pharmacology. In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs. Here we show that the anti-inflammatory lipid lipoxin A 4 is an endogenous allosteric enhancer of the CB 1 cannabinoid receptor. Lipoxin A 4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB 1 receptor (vs. 3 H-SR141716A), and did not alter endocannabinoid metabolism (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating …

Cannabinoid receptorAllosteric regulationAnti-Inflammatory AgentsSpatial BehaviorEndogenyAmyloidogenic ProteinsMice TransgenicBiologyPharmacologyReceptors G-Protein-Coupled03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineReceptor Cannabinoid CB1In vivoMemoryCommentariesAnimalsReceptor030304 developmental biologyInflammationMice Knockout0303 health sciencesMultidisciplinarymusculoskeletal neural and ocular physiologyBrainAnandamideURB597Biological SciencesEndocannabinoid system3. Good healthLipoxinsMice Inbred C57BLKineticsNeuroprotective Agentschemistrynervous systemlipids (amino acids peptides and proteins)030217 neurology & neurosurgerypsychological phenomena and processesAllosteric SiteEndocannabinoidsProceedings of the National Academy of Sciences of the United States of America
researchProduct

Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma.

2008

It has recently been shown that cannabinoids induce growth inhibition and apoptosis in different tumour cell lines. In the current study, the effects of WIN 55,212-2 (WIN), a synthetic and potent cannabinoid receptor agonist, are investigated in hepatoma HepG2 cells and a possible signal transduction pathway is proposed. In these cells, WIN induces a clear apoptotic effect which was accompanied by up-regulation of the death-signalling factors Bax, Bcl-X(S), t-Bid and down-regulation of the survival factors survivin, phospho-AKT, Hsp72 and Bcl-2. Moreover, WIN-induced apoptosis is associated with JNK/p38 MAPK pathway activation and mitochondrial depolarisation demonstrated by a cytofluorimet…

Cannabinoid receptorCarcinoma HepatocellularCell SurvivalPyridinesmedicine.medical_treatmentp38 mitogen-activated protein kinasesMorpholinesApoptosisBiologyNaphthalenesBiochemistryReceptor Cannabinoid CB2Membrane Microdomainscannabinoids PPARgamma factor apoptosis cancer cellsSettore BIO/10 - BiochimicaCell Line TumorSurvivinmedicineHumansAnilidesViability assayCannabinoidsLiver NeoplasmsGeneral MedicineCell biologyBenzoxazinesPPAR gammaApoptosisCancer cellBenzamidesCannabinoidSignal transductionApoptosis Regulatory ProteinsProtein KinasesSignal TransductionBiochimie
researchProduct

The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells

2006

Endocannabinoids exert an important neuromodulatory role via presynaptic cannabinoid CB1receptors and may also participate in the control of neural cell death and survival. The function of the endocannabinoid system has been extensively studied in differentiated neurons, but its potential role in neural progenitor cells remains to be elucidated. Here we show that the CB1receptor and the endocannabinoid-inactivating enzyme fatty acid amide hydrolase are expressed, bothin vitroandin vivo, in postnatal radial glia (RC2+cells) and in adult nestin type I (nestin+GFAP+) neural progenitor cells. Cell culture experiments show that CB1receptor activation increases progenitor proliferation and differ…

Cannabinoid receptorCellular differentiationMorpholinesApoptosisNerve Tissue ProteinsBiologyNaphthalenesHippocampusAmidohydrolasesNestinMiceIntermediate Filament ProteinsReceptor Cannabinoid CB1Cannabinoid Receptor ModulatorsGlial Fibrillary Acidic ProteinAnimalsProgenitor cellEnzyme InhibitorsNeural cellCells CulturedProgenitorMice KnockoutNeuronsCannabinoidsmusculoskeletal neural and ocular physiologyGeneral NeuroscienceStem CellsCell DifferentiationArticlesNestinEndocannabinoid systemNeural stem cellBenzoxazinesRatsnervous systemAstrocytesBenzamideslipids (amino acids peptides and proteins)CarbamatesNeurosciencepsychological phenomena and processesEndocannabinoids
researchProduct

Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis.

2011

Abstract Cannabinoid CB1 receptors (CB1Rs) regulate the neurodegenerative damage of experimental autoimmune encephalomyelitis (EAE) and of multiple sclerosis (MS). The mechanism by which CB1R stimulation exerts protective effects is still unclear. Here we show that pharmacological activation of CB1Rs dampens the tumor necrosis factor α (TNFα)-mediated potentiation of striatal spontaneous glutamate-mediated excitatory postsynaptic currents (EPSCs), which is believed to cogently contribute to the inflammation-induced neurodegenerative damage observed in EAE mice. Furthermore, mice lacking CB1Rs showed a more severe clinical course and, in parallel, exacerbated alterations of sEPSC duration af…

Cannabinoid receptorEncephalomyelitis Autoimmune ExperimentalPolyunsaturated Alkamidesmedicine.medical_treatmentImmunologyExcitotoxicityGlutamic AcidArachidonic AcidsPharmacologyBiologymedicine.disease_causeReceptors N-Methyl-D-AspartateReceptors Tumor Necrosis FactorAmidohydrolasesEtanerceptBehavioral Neurosciencechemistry.chemical_compoundMiceReceptor Cannabinoid CB1Fatty acid amide hydrolaseCannabinoid Receptor ModulatorsmedicineAnimalsDronabinolReceptors AMPA6-Cyano-7-nitroquinoxaline-23-dioneMice KnockoutNeuronsEndocrine and Autonomic SystemsTumor Necrosis Factor-alphaNeurodegenerationExperimental autoimmune encephalomyelitisExcitatory Postsynaptic PotentialsAnandamidemedicine.diseaseEndocannabinoid systemCorpus StriatumMice Inbred C57BLchemistryImmunoglobulin GImmunologyNerve DegenerationSettore MED/26 - NeurologiaFemaleCannabinoidDizocilpine MaleateEndocannabinoidsBrain, behavior, and immunity
researchProduct

Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus

2013

Type 1 cannabinoid receptor (CB1) is expressed in different neuronal populations in the mammalian brain. In particular, CB1 on GABAergic or glutamatergic neurons exerts different functions and display different pharmacological properties in vivo. This suggests the existence of neuron-type specific signalling pathways activated by different subpopulations of CB1. In this study, we analysed CB1 expression, binding and signalling in the hippocampus of conditional mutant mice, bearing CB1 deletion in GABAergic (GABA-CB1-KO mice) or cortical glutamatergic neurons (Glu-CB1-KO mice). Compared to their wild-type littermates, Glu-CB1-KO displayed a small decrease of CB1 mRNA amount, immunoreactivity…

Cannabinoid receptorG proteinmedicine.medical_treatmentHippocampusBiologyHippocampal formationHippocampusBiochemistryMice03 medical and health sciencesCellular and Molecular NeuroscienceGlutamatergic0302 clinical medicineGTP-binding protein regulatorsReceptor Cannabinoid CB1GTP-Binding ProteinsmedicineAnimalsGABAergic Neurons030304 developmental biologyMice Knockout0303 health sciencesCannabinoidsmusculoskeletal neural and ocular physiologyfood and beveragesMice Inbred C57BLnervous systemGABAergiclipids (amino acids peptides and proteins)CannabinoidNeurosciencepsychological phenomena and processes030217 neurology & neurosurgeryProtein BindingSignal TransductionJournal of Neurochemistry
researchProduct

WIN55,212-2-induced expression of Mir-29b1 favours the suppression of osteosarcoma cell migration in a SPARC-independent manner

2019

WIN55,212-2 (WIN) is a synthetic agonist of cannabinoid receptors that displays promising antitumour properties. The aim of this study is to demonstrate that WIN is able to block the migratory ability of osteosarcoma cells and characterize the mechanisms involved. Using wound healing assay and zymography, we showed that WIN affects cell migration and reduces the activity of the metalloproteases MMP2 and MMP9. This effect seemed to be independent of secreted protein acidic and rich in cysteine (SPARC), a matricellular protein involved in tissue remodeling and extracellular matrix deposition. SPARC release was indeed prevented by WIN, and SPARC silencing by RNA interference did not influence …

Cannabinoid receptorMorpholinesAntineoplastic AgentsMMP9NaphthalenesCatalysisArticlelcsh:ChemistryInorganic ChemistryExtracellular matrixExtracellular VesiclescannabinoidsDownregulation and upregulationCell MovementCell Line TumorSettore BIO/10 - BiochimicaGene silencingHumansOsteonectinCell migrationPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyCannabinoidSpectroscopyCell ProliferationOsteosarcomaChemistryCell growthOrganic ChemistryMatricellular proteinCell migrationSPARCGeneral MedicineComputer Science ApplicationsCell biologyBenzoxazinesMiR-29b1MicroRNAslcsh:Biology (General)lcsh:QD1-999
researchProduct

The endocannabinoid system in anxiety, fear memory and habituation.

2011

Evidence for the involvement of the endocannabinoid system (ECS) in anxiety and fear has been accumulated, providing leads for novel therapeutic approaches. In anxiety, a bidirectional influence of the ECS has been reported, whereby anxiolytic and anxiogenic responses have been obtained after both increases and decreases of the endocannabinoid tone. The recently developed genetic tools have revealed different but complementary roles for the cannabinoid type 1 (CB1) receptor on GABAergic and glutamatergic neuronal populations. This dual functionality, together with the plasticity of CB1 receptor expression, particularly on GABAergic neurons, as induced by stressful and rewarding experiences…

Cannabinoid receptormedicine.drug_classclassical conditioninggamma-aminobutyric acidglutamateAnxietyAnxiolyticstressReceptor Cannabinoid CB1MemoryCannabinoid Receptor ModulatorsmedicineAnimalsHumansneuronal plasticityPharmacology (medical)HabituationendocannabinoidsHabituation PsychophysiologicPharmacologyExtinction (psychology)FearArticleshabituationEndocannabinoid systemPsychiatry and Mental healthAnxiogenicnervous systemcannabinoid CB1 receptorAnxietyMemory consolidationlipids (amino acids peptides and proteins)medicine.symptomPsychologyNeuroscienceJournal of psychopharmacology (Oxford, England)
researchProduct